BILL Holdings Sale Talk Lifts Shares

BILL Holdings sale speculation, driven by activist pressure and an earnings beat, lifted shares more than 13% and prompted advisers to gauge interest.

November 12, 2025·2 min read
View all news articles
Flat vector of a bill-pay terminal merging with a tilted boardroom ledger to evoke BILL Holdings sale review.

KEY TAKEAWAYS

  • Following reports of a potential sale and activist pressure, shares rose more than 13%.
  • Q1 FY2026 revenue was $395.7 million and adjusted EPS $0.61 beat the $0.51 consensus.
  • Management raised FY2026 adjusted EPS to $2.11–$2.25 and revenue guidance to about $1.6 billion.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

BILL Holdings (BILL) shares rose more than 13% on Nov. 12 after reports of a potential sale and pressure from activist investors. The company had earlier reported a quarterly earnings beat that led management to raise its guidance.

Sale Review and Activist Pressure

BILL Holdings is exploring a potential sale and other strategic alternatives, engaging financial advisers to gauge interest from potential buyers. The process remains in its early stages, and there is no certainty a transaction will occur. As of Nov. 12, the company had not disclosed any formal merger-and-acquisition process or regulatory filings, nor commented on the reported review.

Activist investors have intensified pressure on BILL. Starboard Value disclosed an 8.5% stake in September 2025 and nominated four board members to push for strategic changes. Elliott Investment Management has also built a significant position and advocated for a sale. In October, BILL appointed four new independent directors, including a Starboard nominee.

Following reports on Nov. 11 that BILL was exploring a sale, shares surged. The company’s market capitalization was roughly $4.2–$4.7 billion in November 2025.

Quarterly Results and Guidance

BILL reported Q1 fiscal 2026 results on Nov. 6, posting revenue of $395.7 million, up 10% year over year, and adjusted earnings of $0.61 per share, beating the $0.51 consensus. Gross profit was $318.7 million, reflecting an 80.5% margin. The company recorded a GAAP operating loss of $20.7 million but reported non-GAAP operating income of $68.2 million.

Management raised full-year guidance to adjusted earnings per share of $2.11–$2.25, up from $2.00–$2.20, and revenue guidance to $1.597–$1.627 billion, narrowing the prior range. Second-quarter adjusted EPS guidance was set at $0.54–$0.57. Executives cited partnerships with NetSuite, Paychex, and Acumatica, along with AI-driven product innovation, as drivers of continued momentum.

The combination of activist pressure and an improved financial outlook supports the strategic review and likely increases BILL’s appeal to potential acquirers.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

Kevin Warsh Fed Chair Advances After Committee Vote

Kevin Warsh Fed Chair Advances After Committee Vote

Kevin Warsh Fed chair nomination advanced from committee to the full Senate, making confirmation timing a near-term market variable ahead of the June FOMC.

Uber Hotel Bookings Expand With Expedia Partnership

Uber Hotel Bookings Expand With Expedia Partnership

Uber hotel bookings with Expedia and AI features add in-app lodging and Uber One credits, strengthening membership monetization and cross-sell signals.

Microsoft Earnings Preview: Azure and AI

Microsoft Earnings Preview: Azure and AI

Microsoft earnings preview puts focus on Azure growth and elevated AI CapEx and the $81.4 billion revenue consensus for margin and flow cues.

Pershing Square IPO Debuts on NYSE

Pershing Square IPO Debuts on NYSE

Pershing Square IPO began trading on April 29, 2026, raising $5.0 billion and adding listed supply that will affect conversion mechanics and liquidity.

KONE to Acquire TK Elevator

KONE to Acquire TK Elevator

KONE to Acquire TK Elevator; investors will watch governance, financing and regulatory timing as the cash-and-stock deal targets synergies before Q2 2027.

AstraZeneca Q1 Results Beat on Oncology Strength

AstraZeneca Q1 Results Beat on Oncology Strength

AstraZeneca Q1 results showed oncology and rare-disease revenue lifted profit and core EPS and should influence near-term investor positioning on guidance